The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Ovarian Cancer: A Heterogeneous Disease
Abstract
Ovarian cancer encompasses a collection of neoplasms with distinct clinicopathological and molecular features and prognosis. Despite there being a variety of ovarian cancer subtypes, these are treated as a single disease. Tremendous efforts have been made to characterize these subtypes and identify tumoral pathways and potential biomarkers for therapeutic strategies. As in other cancer types, tumor heterogeneity appears to be very high across subtypes and within a single tumor, representing a major cause of treatment failure. We describe the morphological and molecular heterogeneity among ovarian cancers and discuss recent advances in our understanding of intratumor heterogeneity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
WHO classification of tumours of female reproductive organs
Kurman, R. J., Carcangiu, M. L., Herrington, C. S., & Young, R. H. (2014) · International Agency for Research on Cancer eBooks · Cited by 1,966
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Parallel progression of primary tumours and metastases
Klein, C. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2627 · Cited by 1,133
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Intratumor Heterogeneity: Evolution through Space and Time
Swanton, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2217 · Cited by 931
Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., Suzuki, M., Sato, I., & Taguchi, K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2584::aid-cncr22>3.0.co;2-5 · Cited by 795
Grading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670
Evolution of the cancer genome
Yates, L. R., & Campbell, P. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3317 · Cited by 640
Vang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., & Muto, M. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2622 · Cited by 485
Bashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L. M., Roth, A., Rosner, J., Shumansky, K., Kalloger, S., Senz, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4230 · Cited by 421
Lee, K. R. C. K., & Scully, R. E. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200011000-00001 · Cited by 343
Clarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280
Anglesio, M. S., Carey, M. S., Köbel, M., MacKay, H., & Huntsman, D. G. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.005 · Cited by 272
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 262
Mucinous tumors of the ovary: a review.
Hart, W. R. (2005) · PubMed · Cited by 246
Mayr, D., Hirschmann, A., Löhrs, U., & Diebold, J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.029 · Cited by 224
Low‐grade serous carcinomas of the ovary contain very few point mutations
Jones, S., Wang, T., Kurman, R. J., Nakayama, K., Velculescu, V. E., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3967 · Cited by 218
Rodríguez, I. M., & Prat, J. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200202000-00001 · Cited by 218
Anglesio, M. S., Kommoss, S., Tolcher, M. C., Clarke, B., Galletta, L., Porter, H., Damaraju, S., Fereday, S., Winterhoff, B. J., Kalloger, S. E., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4088 · Cited by 198
Herzog, T. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0683 · Cited by 188
My approach to and thoughts on the typing of ovarian carcinomas
McCluggage, W. G. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.049478 · Cited by 166
Emerson, R., Sherwood, A., Rieder, M. J., Guenthoer, J., Williamson, D. W., Carlson, C. S., Drescher, C. W., Tewari, M., Bielas, J. H., & Robins, H. S. (2013) · The Journal of Pathology · doi:10.1002/path.4260 · Cited by 151
Ichikawa, Y., Nishida, M., Suzuki, H., Yoshida, S., Tsunoda, H., Kubo, T., Uchida, K., & Miwa, M. (1994) · PubMed · Cited by 144
PARP inhibitors in ovarian cancer
Ledermann, J. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw094 · Cited by 132
Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms
Maeda, D., & Shih, I. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827bc24d · Cited by 131
Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis
Lee, Y.-Y., Kim, T., Kim, M., Kim, H.-J., Song, T., Kim, M. K., Choi, C. H., Lee, J., Bae, D., & Kim, B. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.009 · Cited by 122
Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates
Gurung, A., Hung, T., Morin, J., & Gilks, C. B. (2012) · Histopathology · doi:10.1111/his.12033 · Cited by 117
Khalique, L., Ayhan, A., Weale, M. E., Jacobs, I. J., Ramus, S. J., & Gayther, S. A. (2006) · The Journal of Pathology · doi:10.1002/path.2112 · Cited by 117
Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (Review)
Kobayashi (2009) · Oncology Reports · doi:10.3892/or_00000429 · Cited by 115
Ovarian cancer: a focus on management of recurrent disease
Herzog, T. J., & Pothuri, B. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0637 · Cited by 112
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes
McBride, D. J., Etemadmoghadam, D., Cooke, S. L., Alsop, K., George, J., Butler, A. P., Cho, J., Galappaththige, D., Greenman, C., Howarth, K., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4042 · Cited by 102
Napsin A is a specific marker for ovarian clear cell adenocarcinoma
Yamashita, Y., Nagasaka, T., Naiki‐Ito, A., Sato, S., Suzuki, S., Toyokuni, S., Ito, M., & Takahashi, S. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.61 · Cited by 92
Lee, J., Yoon, J.-K., Kim, B., Kim, S., Kim, M. A., Lim, H., Bang, D., & Song, Y. S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1077-4 · Cited by 92
Braicu, E. I., Sehouli, J., Richter, R., Pietzner, K., Denkert, C., & Fotopoulou, C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.455 · Cited by 89
Boyd, C., & McCluggage, W. G. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31823732a9 · Cited by 88
Wu, C. H., Mao, T., VANG, R. S., Ayhan, A., Wang, T., Kurman, R. J., & Shih, I. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31823f8482 · Cited by 86
Genomic and transcriptomic plasticity in treatment-naïve ovarian cancerPreprint
Hoogstraat, M., de Pagter, M. S., Cirkel, G. A., van Roosmalen, M. J., Harkins, T. T., Duran, K. J., Kreeftmeijer, J., Renkens, I., Witteveen, P. O., Lee, C. C., et al. (2013) · Genome Research · doi:10.1101/gr.161026.113 · Cited by 86
Lu, F., Gilks, C. B., Mulligan, A. M., Ryan, P. M., Allo, G., Sy, K., Shaw, P. A., Pollett, A. F., & Clarke, B. A. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31824fe2aa · Cited by 74
Bamias, A., Sotiropoulou, M. G., Zagouri, F., Trachana, P., Sakellariou, K., Kostouros, E., Kakoyianni, K., Rodolakis, A., Vlachos, G. D., Haidopoulos, D. A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.023 · Cited by 50
Ovarian clear cell carcinoma—bad endometriosis or bad endometrium?
Gounaris, I., Jones, D. S., & Brenton, J. D. (2011) · The Journal of Pathology · doi:10.1002/path.2970 · Cited by 41
Early Preinvasive Lesions in Ovarian Cancer
Chene, G., Lamblin, G., Bail-Carval, K. L., Chabert, P., Bakrin, N., & Mellier, G. (2014) · BioMed Research International · doi:10.1155/2014/639252 · Cited by 33
Endometriosis-associated Ovarian Cancer: A Distinct Clinical Entity?
Bounous, V. E., Ferrero, A., Fuso, L., Ravarino, N., Ceccaroni, M., Menato, G., & Biglia, N. (2016) · PubMed · Cited by 27
Cited by
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
Zhang, M., Cheng, S., Jin, Y., Zhao, Y., & Wang, Y. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188503 · Cited by 384
Synthetic Lethality in Ovarian Cancer
Chandrasekaran, A., & Elias, K. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0500 · Cited by 41
Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
Li, J., Hu, H., He, J., Hu, Y., Liu, M., Cao, B., Chen, D., Ye, X., Zhang, J., Zhang, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101825 · Cited by 4
Metadata
- Authors
- Kossaï, M., Leary, A., Scoazec, J.-Y., & Genestie, C.
- Venue
- Pathobiology
- Publisher
- S. Karger AG
- Published
- 2017-10-12
- Volume
- 85
- Issue
- 1-2
- Pages
- 41-49
- ISSN
- 1015-2008 (ISSN-L)
- 1423-0291
- OpenAlex
- W2761765094
- Cited by
- 388
- References
- 50
- FWCI
- 14.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.